🇺🇸 FDA
Pipeline program

NMRA-323511

NMRA-323511-104

Phase 1 small_molecule completed

Quick answer

NMRA-323511 for Alzheimer's Disease is a Phase 1 program (small_molecule) at Neumora Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Neumora Therapeutics
Indication
Alzheimer's Disease
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials